Endocrine Abstracts

Case 1: A 65-year-old man was admitted with symptomatic hypocalcaemia (corrected calcium of 1.65 mmol/l, PTH 46.6 (1.6–6.8) pmol/l, and vitamin D 51.4 (50–150) nmol/l)) 5 days following denosumab initiation. He had a diagnosis of probable urothelial carcinoma with associated osteoblastic metastases, and 10 days prior to this admission had been treated for hypercalcaemia (corrected calcium of 3.04 (2.20–2.60) mmol/l) with i.v. fluids following which denosumab was...